Superior to Oracea®

Treatment of the Pimples and Bumps of Rosacea From

Actual EMROSI™ Patients

Before and After Treatment

with EMROSI™

Before Treatment

Patient images from the EMROSI™ clinical studies. Individual results may vary.

Patient A After
Patient A Before

After Week 16

Patient images from the EMROSI™ clinical studies. Individual results may vary.

Before Treatment

Patient images from the EMROSI™ clinical studies. Individual results may vary.

Patient B After
Patient B Before

After Week 16

Patient images from the EMROSI™ clinical studies. Individual results may vary.

Before Treatment

Patient images from the EMROSI™ clinical studies. Individual results may vary.

Patient C After
Patient C Before

After Week 16

Patient images from the EMROSI™ clinical studies. Individual results may vary.

Before Treatment

Patient images from the EMROSI™ clinical studies. Individual results may vary.

Patient D After
Patient D Before

After Week 16

Patient images from the EMROSI™ clinical studies. Individual results may vary.

Proven superior

For nearly 20 years, the only FDA-approved oral treatment for rosacea was Oracea® (doxycycline, 40 mg). But with once-daily EMROSI™, there's finally a better option.

In studies, EMROSI™ was proven superior to Oracea® for treating the pimples and bumps of rosacea, with a safety profile that's similar to placebo.

Clinical Study Results

outperformed chart
62.7%

of patients had clear or almost clear skin on EMROSI™ vs 39% on Oracea® after 16 weeks of treatment

% of Patients With Clear or Almost Clear Skin at Week 16

% of Patients with Clear or Almost Clear Skin at Week 16

Pooled Phase 3 Clinical Trial Data

Clinical Study Results

outperformed chart
-19

fewer pimples and bumps for patients on EMROSI™
vs -14.8 fewer on Oracea® after 16 weeks of treatment*

Reduction of Pimples & Bumps of Rosacea at Week 16

Inflammatory Lesion Reduction at Week 16

Pooled Phase 3 Clinical Trial Data

*The average patient in the clinical trial started with 25 pimples and bumps of rosacea.

Study design: Two identically designed, randomized, double-blind, active- and placebo-controlled Phase 3 trials, including 653 total participants, to compare the impact of oral EMROSI™, Oracea®, and placebo as standalone treatments in adults with rosacea.

Patients taking EMROSI™

started seeing improvement
in as little as

2

weeks.

A Safety Profile Similar to Placebo

EMROSI™ demonstrated a safety profile similar to placebo. The frequency of side effects was low, and most were reported as mild or moderate.

See Safety Data
Expand

INDICATION

EMROSI is a prescription medicine used to treat adults with pimples and bumps (inflammatory lesions) caused by a condition called rosacea.

EMROSI should not be used for the treatment of infections. It is not known if EMROSI is safe and effective in children.

IMPORTANT SAFETY INFORMATION

  • Do not take EMROSI if you are allergic to any tetracycline medicines.
  • Before using EMROSI, tell your healthcare provider about all the other medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. EMROSI and other medicines may affect each other and cause serious side effects.
  • Do not use EMROSI if you are pregnant, may become pregnant or are nursing. If you become pregnant while using EMROSI, talk to your doctor. Tetracycline medicine when taken by mouth during pregnancy, infancy and/or childhood up to the age of 8 years may permanently discolor teeth (yellow-gray-brown) and may slow the growth of bones.
  • Protect your skin from the sun while using EMROSI. Avoid sunlight or artificial sunlight such as sunlamps or tanning beds. Stop using EMROSI if you get a sunburn.
  • When taken by mouth, minocycline may cause feelings of lightheadedness, dizziness or a spinning feeling. You should not drive or operate dangerous machinery if you have these symptoms.

EMROSI is an extended-release capsule that contains minocycline, a tetracycline medicine. Tetracyclines, when taken by mouth, may cause serious side effects, including: serious skin or allergic reactions which can cause skin redness, rash, hives, sores in your mouth, or your skin blisters and peels; swelling of your face, eyes, lips, tongue, or throat; trouble swallowing or breathing; blood in your urine; fever, yellowing of the skin or the whites of your eyes (jaundice), dark colored urine; pain on the right side of the stomach area (abdominal pain); chest pain or abnormal heartbeats; swelling in your legs, ankles, and feet; diarrhea which may be caused by an infection that can cause watery or bloody stools; loss of appetite; tiredness; unexplained bleeding or bleeding more easily than normal; confusion; sleepiness; vision changes, including blurred vision, double vision, or permanent vision loss; unusual headaches; fever; rash; joint pain; body weakness. Call your doctor right away if these side effects occur.

The most common side effects of EMROSI include stomach upset or burning (dyspepsia) after eating or drinking.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088. You may also report side effects to Journey Medical Corporation at 1‑855‑531‑1859.

Please see full Prescribing Information, including Patient Product Information.

Close This site uses cookies, and your privacy choice is important to us.

We use cookies to improve your experience, produce audience statistics, offer you services tailored to your interests, and provide features associated with social media. You can change your preferences at any time on the site.

Accept all cookies